II. Mechanism
-
Sedative Hypnotic
- Potentiates Gamma-Aminobutyric Acid receptors
- No Analgesic effect
- Administer concurrent Analgesics (typically given 20-30 minutes prior to Propofol start)
-
Drug Abuse potential (especially among anesthesiologists, nurse anesthetists, emergency medicine staff, dentists)
- Increases Dopamine levels which may reinforce addiction
- Increases Serotonin levels which may be Hallucinogenic
- References
- Majoewsky (2012) EM:RAP 12(1): 3
III. Precautions
- See Procedural Sedation and Analgesia (PSAA)
- Propofol has no Analgesic effect, and therefore Opioid Analgesics are often used before Propofol
- Propofol (esp. with concurrent Opioids) increases the risk of cardiopulmonary depression (Hypoxia, Hypotension)
- Close monitoring is critical (second provider skilled in airway management is preferred)
- Consider pre-procedure crystalloid bolus of 500 ml (or 10-20 ml/kg)
- Consider oxygen via nasal canula at 2 L/min
- Suction, Bag-valve mask, Nasopharyngeal Airway, and intubation equipment should be ready for use
- Consider Capnography
IV. Pharmacokinetics
- Rapid onset and short Half-Life
- Lipid-soluble and crosses blood-brain barrier
- Onset: 30-45 seconds (<1 minute)
- Duration: 6 minutes on average (5 to 15 minutes, prolonged with repeated dosing)
-
Lipid emulsion bottle is at risk of Bacterial contamination and growth once accessed
- Discard any open bottles after 12 hours
V. Preparation
- See Procedural Sedation
- Second provider skilled in airway management (preferred)
- Preventive measures
- Pre-procedure crystalloid bolus of 500 ml (or 10-20 ml/kg)
- Oxygen via nasal canula at 2 L/min
- Opioid Analgesics given at least 20 minutes before procedure
- Monitoring Equipment
- Pulse Oximetry (Oxygen Saturation and Heart Rate)
- Blood Pressure cuff, manual or automatic cycled every few minutes
- Consider Capnography
- Emergency Equipment
- Wall Suction (typically with yanker catheter tip)
- Bag-valve mask
- Nasopharyngeal Airway
- Intubation equipment (see Advanced Airway)
VI. Dosing: Adults
-
Conscious Sedation (not FDA approved)
- Adult (preferred procedural Sedative)
- Initial: 0.5 to 1 mg/kg IV over 20-30 seconds (typically given as smaller increments)
- Obese patients: Consider 0.7 to 0.8 mg/kg for starting dose
- Thin young patients: Consider 1.5 mg/kg for starting dose (risk of respiratory depression)
- Frail elderly patients: Consider 20-30 mg IV for starting dose
- Next: 0.25 to 0.5 mg/kg IV every 1 to 3 minutes
- Decrease dose in older patients (cummulative required total dose decreases with age)
- Age 18-40 years old: 2 mg/kg total dose
- Age 41-64 years old: 1.7 mg/kg total dose
- Age >64 years old: 1.2 mg/kg total dose
- Patanwala (2013) J Emerg Med 44(4): 823-8 +PMID:23333181 [PubMed]
- Initial: 0.5 to 1 mg/kg IV over 20-30 seconds (typically given as smaller increments)
- Typically no respiratory depression at 1 mg/kg dose
- Amnesia occurs at this dose
- Perform painful procedures immediately following infusion
- Amnestic effect wears off prior to sedation
- Adult (preferred procedural Sedative)
- Propofol Infusion for Procedural Sedation
- Infusion: 100 to 150 mcg/kg/min (6 to 9 mg/kg/h)
- Intubation Sedation (not FDA approved)
- Dose 2 to 2.5 mg/kg IV over 20 to 30 seconds
-
Ventilator sedation in ICU
- Infusion: 5-50 mcg/kg/min
-
Anesthesia
- Age under 55 years old
- Titration: 40 mg IV every 10 seconds until induction achieved
- Typical cummulative total dose: 2 to 2.5 mg/kg
- Maintenance infusion: 100-200 mcg/kg/min
- Age 55 years old or older
- Decrease dose from that list above for younger patients
- Age under 55 years old
VII. Dosing: Children
- Avoid for prolonged ICU use
-
Conscious Sedation (not FDA approved)
- Initial: 1 mg/kg IV (up to 40 mg) over 20-30 seconds (typically given as smaller increments)
- Dose per kilogram typically higher in children than adults for adequate sedation
- Age <3 years: 2 mg/kg
- Older children and teens: 1.5 mg/kg
- May repeat 0.5 to 1 mg/kg IV (up to 20 mg maximum) every 1 to 3 minutes as needed
- Initial: 1 mg/kg IV (up to 40 mg) over 20-30 seconds (typically given as smaller increments)
- Propofol Infusion for Procedural Sedation
- Infusion: 100 to 250 mcg/kg/min (6 to 15 mg/kg/h)
-
Anesthesia (age 3 years and older)
- Typical cummulative total dose: 2.5 to 3.5 mg/kg over 20-30 seconds
- Maintenance infusion: 125-300 mcg/kg/min
VIII. Indications
-
Procedural Sedation and Analgesia (PSAA)
- Indicated for ASA Physical Status Score 2 (non-hypotensive, stable)
-
Rapid Sequence Intubation
- Other agents (e.g. Etomidate, Ketamine) are preferred for emergency department induction (Hypotension risk)
IX. Contraindications: Relative
- See Procedural Sedation and Analgesia (PSAA)
- Age <6 months or weight <5 kg
- Age >75 years old
- ASA Physical Status Class 3 and above
- Soy allergy (soybean allergy) is no longer considered a contraindication
- Egg allergy (egg Lecithin allergy) is no longer considered a contraindication
X. Adverse Effects
-
Propofol Infusion Syndrome
- Seen with prolonged use (not associated with short-term Procedural Sedation and Analgesia)
-
Hypertriglyceridemia (with prolonged infusion)
- Propofol is a lipid-based infusion that contains 1 kcal/ml
- Risk of Acute Pancreatitis
- Cardiopulmonary adverse effects (reduced by administering with lower dose and slower titration)
- Respiratory depression
- More common in older adults
- Close monitoring by a second provider skilled in airway management is preferred
- Consider oxygen via nasal canula at 2 L/min
- Suction, Bag-valve mask, Nasopharyngeal Airway, and intubation equipment should be ready for use
- Consider Capnography
- Transient Hypotension and myocardial depression
- Systolic Blood Pressure drops 10-18 mmHg, Diastolic Blood Pressure drops 10-16 mmHg
- Consider pre-procedure crystalloid bolus of 500 ml (or 10-20 ml/kg)
- Increase time (>20 minutes) between IV Opioids and Propofol
- Consider alternative Sedatives (e.g. Etomidate or Ketamine) in hypotensive patients
- Phenylephrine may be used to counter the hypotensive effects of Propofol
- Respiratory depression
-
Overdose
- No antidote
- Manage with ABC Management and supportive care
XI. Safety
XII. Resources
XIII. References
- Acker, Koval and Leeper (2017) Crit Dec Emerg Med 31(4): 3-13
- Miller (2019) Ann Emerg Med 73(5): 470-80 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
Definition (CHV) | a kind of short-acting anesthetic |
Definition (NCI) | A hypnotic alkylphenol derivative. Formulated for intravenous induction of sedation and hypnosis during anesthesia, propofol facilitates inhibitory neurotransmission mediated by gamma-aminobutyric acid (GABA). This agent is associated with minimal respiratory depression and has a short half-life with a duration of action of 2 to 10 minutes. |
Definition (PDQ) | A hypnotic alkylphenol derivative. Formulated for intravenous induction of sedation and hypnosis during anesthesia, propofol facilitates inhibitory neurotransmission mediated by gamma-aminobutyric acid (GABA). This agent is associated with minimal respiratory depression and has a short half-life with a duration of action of 2 to 10 minutes. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=461189&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=461189&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29384" NCI Thesaurus) |
Definition (MSH) | An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D015742 |
SnomedCT | 387423006, 74674007 |
LNC | LP31828-4, MTHU015674 |
English | Disoprofol, Propofol, 2,6 Diisopropylphenol, 2,6-Diisopropylphenol, Phenol, 2,6-bis(1-methylethyl)-, 2,6-Bis(1-methylethyl)phenol, propofol (medication), PROPOFOL, Propofol [Chemical/Ingredient], propofol, Propofol (product), Propofol (substance) |
Swedish | Propofol |
Czech | propofol |
Finnish | Propofoli |
Russian | DIZOPROFOL, PROPOFOL, ДИЗОПРОФОЛ, ПРОПОФОЛ |
Japanese | プロポホル, 2,6-ジイソプロピルフェノール, ジソプロホル, プロポフォール, ジソプロフォール |
German | BIS METHYLETHYL PHENOL 02 06 01, 2,6-Bis(1-Methylethyl)Phenol, Diisoprofol, Propofol |
Polish | Propofol |
Spanish | propofol (producto), propofol (sustancia), propofol, Disoprofol, Propofol |
French | Propofol |
Italian | Propofol |
Portuguese | Disoprofol, Propofol |
Ontology: Diprivan (C0678120)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D015742 |
English | diprivan, Diprivan, Astra Brand of Propofol, AstraZeneca Brand of Propofol, Disoprivan, Zeneca Brand of Propofol |